$HRTIS #Herantis Pharma Oyj Herantis Pharma - 2019 progress made; next up, CDNF data: Herantis Pharma progressed on multiple levels in 2019. With the main study of the Phase I/II cerebral dopamine neurotrophic factor (CDNF) study now… https://t.co/OorD2yZN6M #equity #stocks https://t.co/8dXRj463Pi